Creative Biolabs Enhances Retrovirus Research with Expanded HIV and HTLV Antibody Portfolio

Creative Biolabs has significantly expanded its specialized antibody portfolio, providing researchers with essential tools to investigate structural and envelope proteins from HIV-1, HIV-2, and HTLV-1. These high-quality reagents are engineered to support critical areas of virology and immunology, including viral entry studies, epitope recognition, and the development of sophisticated diagnostic assays. By focusing on specific viral targets, the company aims to accelerate advancements in vaccine design and pathogenesis research.

Key additions to the product line include antibodies targeting the HIV-1 gp140 protein, which is vital for broadly neutralizing antibody research, and the HIV-2 gp36 antigen, which assists in studying distinct clinical challenges and cross-reactivity. Additionally, the inclusion of anti-HTLV-1 gag p19 antibodies provides a robust solution for researchers analyzing the causative agent of adult T-cell leukemia/lymphoma. These tools are optimized for standard laboratory applications such as Western blot, ELISA, and immunohistochemistry.

A senior scientist at Creative Biolabs noted that the expansion is driven by the need for reagents that offer high specificity across diverse experimental formats. As global research efforts continue to address the complexities of human retroviruses, these expanded resources offer scientists the precision necessary to explore viral mechanisms. All products are intended exclusively for research use, reinforcing Creative Biolabs' commitment to supporting the global scientific community in infectious disease breakthroughs.